Larazotide
Larazotide Acetate (AT-1001)
A tight junction regulator that reduces intestinal permeability. In clinical trials for celiac disease and used off-label for leaky gut and inflammatory bowel conditions.
Mechanism of Action
Larazotide blocks zonulin receptors on intestinal epithelial cells, preventing zonulin-mediated tight junction opening. This reduces intestinal permeability and the translocation of antigens and endotoxins across the gut barrier.
Health Claims & Evidence
Reduces intestinal permeability (leaky gut)
Reduces celiac disease symptoms
Reduces systemic inflammation from gut permeability
Short-Term Effects
Reduced gut symptoms, improved intestinal barrier function within weeks.
Long-Term Effects
Sustained gut barrier improvement and reduced systemic inflammation.
Side Effects
Generally well-tolerated. Mild GI symptoms in some patients.
Contraindications
Limited data outside celiac disease.
This profile is provided for educational research only. It is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Verify primary sources and consult a qualified healthcare professional for medical decisions.
Research Papers
Larazotide acetate in celiac disease
Kelly et al. · Alimentary Pharmacology & Therapeutics · 2013
Educational research only. This profile is not a treatment recommendation or dosing guide. Human evidence, safety information and regulatory status vary by substance. Consult a qualified healthcare professional for medical decisions.
Related Peptides
Explore the research further
Our AI Research Advisor can help you explore the evidence on Larazotide and related peptides, and prepare an educational research summary.
Explore Research